Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
AAPS PharmSciTech ; 22(4): 146, 2021 Apr 30.
Artículo en Inglés | MEDLINE | ID: mdl-33929614

RESUMEN

In vitro and in vivo studies of gliclazide (GLZ)-loaded freeze-dried alginate-gelatin (AL-GL) beads were carried out, aiming to modify its oral bioavailability. Crosslinked freeze-dried GLZ AL-GL beads (particle size: 1.5- and 3.0-mm) were prepared. In vitro evaluation of GLZ AL-GL beads included SEM, DSC, FT-IR, and release rate study in gradient media. In vivo study was single-dose (4 mg/kg), randomized, parallel-group design, two-treatment (T: test GLZ AL-GL beads and R: reference product Diamicron® 30-mg MR tablet) conducted in 96 healthy rats. Each group was subdivided into 2 sub-groups (G1 and G2) having different blood sampling schemes for up to 72 h. Assessment of level A in-vitro-in-vivo correlation (IVIVC) model was carried out. AL-GL beads successfully increased GLZ release rate compared to R. GLZ percent released (Q4h) was 109.34, 86.85, and 43.43% for 1.5-mm and 3.0-mm beads and R, respectively. DSC analysis confirmed the interaction of AL-GL via crosslinking. No chemical interaction of GLZ has occurred as proved by FT-IR. Relative bioavailability (T/R) for AUC0-∞ was 132.45% for G1 and 146.16% for G2. No significant differences between T and R in the primary pharmacokinetic parameters were determined. Tmax values were found to be earlier in the case of G1 than those of G2. A secondary absorption peak of GLZ was clearly detected in the case of R while its sharpness was minimized in T. High IVIVC was established, and hence, the proposed in vitro release model perfectly correlated with the in vivo study. The current study design might be a platform to enable panoramic view for GLZ variability in vivo.


Asunto(s)
Composición de Medicamentos/métodos , Gliclazida/síntesis química , Gliclazida/farmacocinética , Tamaño de la Partícula , Animales , Liberación de Fármacos/fisiología , Hipoglucemiantes/síntesis química , Hipoglucemiantes/farmacocinética , Técnicas In Vitro , Masculino , Ratas , Ratas Wistar , Espectroscopía Infrarroja por Transformada de Fourier/métodos
2.
Eur J Pharm Biopharm ; 119: 56-67, 2017 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-28583588

RESUMEN

The formation of molecularly dispersed amorphous solid dispersions by the hot-melt extrusion technique relies on the thermal and mechanical energy inputs, which can cause chemical degradation of drugs and polymeric carriers. Additionally, drug degradation may be exacerbated as drugs convert from a more stable crystalline form to a higher energy amorphous form. Therefore, it is imperative to study how drug degrades and evaluate methods to minimize drug degradation during the extrusion process. In this work, gliclazide was used as a model thermally labile drug for the degradation kinetics and process optimization studies. Preformulation studies were conducted using thermal analyses, and liquid chromatography-mass spectroscopy to identify drug degradation pathways and to determine initial extrusion conditions. Formulations containing 10% drug and 90% AFFINISOL™ HPMC HME 100LV were then extruded using a twin screw extruder, and the extrudates were characterized using X-ray powder diffraction, modulated dynamic scanning calorimetry, and potency testing to evaluate physicochemical properties. The energies of activation for both amorphous gliclazide, crystalline gliclazide, and gliclazide solution were calculated using the Arrhenius equation to further guide the extrusion optimization process. Preformulation studies identify two hydrolysis degradation pathways of gliclazide at elevated temperatures. The activation energy study indicates a significantly higher degradation rate for the amorphous gliclazide compared to the crystalline form. After optimization of the hot-melt extrusion process, including improved screw designs, machine setup, and processing conditions, gliclazide amorphous solid dispersion with ∼95% drug recovery was achieved. The ability to process thermally labile drugs and polymers using hot-melt extrusion will significantly expand the possible applications of this manufacturing process.


Asunto(s)
Química Farmacéutica/métodos , Gliclazida/análisis , Gliclazida/síntesis química , Calor , Rastreo Diferencial de Calorimetría/métodos , Termogravimetría/métodos , Difracción de Rayos X/métodos
3.
Pak J Pharm Sci ; 18(4): 35-40, 2005 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16380356

RESUMEN

Gliclazide is a well known agent used for NIDDM. Present paper reports the synthesis and characterization of its metal complexes with magnesium, calcium, chromium, manganese, iron, nickel, copper, zinc and cadmium. These complexes were characterized through physical characteristics, IR, H(1)-NMR, and atomic absorption spectroscopic studies.


Asunto(s)
Gliclazida/química , Hipoglucemiantes/química , Metales/química , Fenómenos Químicos , Química Física , Gliclazida/síntesis química , Hipoglucemiantes/síntesis química , Espectroscopía de Resonancia Magnética , Espectrofotometría Atómica , Espectrofotometría Infrarroja , Espectrofotometría Ultravioleta
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...